Lv32
248 积分 2026-01-27 加入
Trastuzumab Deruxtecan in Residual HER2-Positive Early Breast Cancer
5天前
已完结
Trastuzumab Deruxtecan in Residual HER2-Positive Early Breast Cancer
5天前
已完结
Survival with Trastuzumab Emtansine in Residual HER2-Positive Breast Cancer
6天前
已完结
Trastuzumab Botidotin Versus Trastuzumab Emtansine in Human Epidermal Growth Factor Receptor 2-Positive Advanced Breast Cancer: A Phase III, Open-Label, Randomized Controlled Trial
19天前
已关闭
Cancer burden and control in China: landscape, trends and challenges
23天前
已完结
Sacituzumab govitecan and stereotactic radiosurgery in the management of HER2 negative breast cancer brain metastases: a multi-institutional report
23天前
已完结
Targeting the host immune system: PD-1 and PD-L1 antibodies and breast cancer
1个月前
已关闭
Carboplatin in BRCA1/2-mutated and triple-negative breast cancer BRCAness subgroups: the TNT Trial
1个月前
已完结
Carboplatin in BRCA1/2-mutated and triple-negative breast cancer BRCAness subgroups: the TNT Trial
1个月前
已完结
皖公网安备34019202002308
